Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
0.5 μg/mL |
5 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Human Brain Tissue Slide(GTX22203) , Rat Brain Tissue Lysate(GTX27942)
Product Note
Numerous isoforms of CAPS1 are known to exist. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
CAPS1 antibody was raised against a 21 amino acid synthetic peptide near the amino terminus of the human CAPS1.The immunogen is located within amino acids 90 - 140 of CAPS1.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
calcium dependent secretion activator , CADPS1 , CAPS , CAPS1 , UNC-31
Cellular Localization
Cell junction, synapse
Background
CAPS1 and its related protein CAPS2 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles; CAPS-deficienct neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. CAPS1 acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4,5-bisphosphate and is thought to be a specific regulator of large dense-core vesicle fusion. Numerous isoforms of CAPS1 are known to exist. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
Database
Research Area